Drug intelligence / Profile preview

TVGN 930

Development stage: Preclinical
Lead developer: Tevogen Bio
Modality: Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

TVGN 930 is an off-the-shelf, genetically unmodified T cell therapy being developed by Tevogen Bio for the treatment of Epstein-Barr virus (EBV)-associated lymphomas. The product leverages CD8+ cytotoxic T lymphocytes to target and eliminate EBV-infected cells. It is part of Tevogen Bio’s pipeline of immune cell therapies designed to address significant unmet needs in oncology and infectious diseases. As of mid-2025, TVGN 930 remains in preclinical development[1][2][3][5][7].

Targets

pMHC-I (Peptide–MHC class I complex)

Beyond the preview

Go deeper on TVGN 930.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TVGN 930.

Explore the full profile